New drug duo aims to control hard-to-treat hepatitis delta
NCT ID NCT06903338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether a combination of two drugs, tobevibart and elebsiran, can control chronic hepatitis delta better than waiting for treatment. About 124 adults with the infection will receive either the combo therapy or delayed treatment. The goal is to see if the combo can clear the virus and normalize liver enzyme levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIRAL HEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Chandler, Arizona, 85224, United States
-
Investigative Site
Los Angeles, California, 90033, United States
-
Investigative Site
Redwood City, California, 94063, United States
-
Investigative Site
San Francisco, California, 94143, United States
-
Investigative Site
DeLand, Florida, 32720, United States
-
Investigative Site
Chicago, Illinois, 60612, United States
-
Investigative Site
Baltimore, Maryland, 21287, United States
-
Investigative Site
Hillsborough, New Jersey, 08844, United States
-
Investigative Site
New York, New York, 10016, United States
-
Investigative Site
New York, New York, 10021, United States
-
Investigative Site
New York, New York, 10029, United States
-
Investigative Site
Murray, Utah, 84107, United States
-
Investigative Site
Seattle, Washington, 98105, United States
-
Investigative Site
Calgary, Alberta, T2N 4Z6, Canada
-
Investigative Site
Montreal, Quebec, H2L 4E9, Canada
-
Investigative Site
Montreal, H2X 1R9, Canada
-
Investigative Site
Ottawa, K1H8L6, Canada
-
Investigative Site
Québec, G1V 4G2, Canada
-
Investigative Site
Vancouver, V6Z 2C7, Canada
-
Investigative Site
Tbilisi, 0102, Georgia
-
Investigative Site
Tbilisi, 0114, Georgia
-
Investigative Site
Tbilisi, 0159, Georgia
-
Investigative Site
Frankfurt, 60590, Germany
-
Investigative Site
Hanover, 30625, Germany
-
Investigative Site
Heidelberg, 69120, Germany
-
Investigative Site
Chisinau, 2025, Moldova
-
Investigative Site
Auckland, 1010, New Zealand
-
Investigative Site
Karachi, 74800, Pakistan
-
Investigative Site
Karachi, 75600, Pakistan
-
Investigative Site
Lahore, 54800, Pakistan
-
Investigative Site
Rawalpindi, 46000, Pakistan
-
Investigative Site
Bucharest, 021105, Romania
-
Investigative Site
Bucharest, 022328, Romania
-
Investigative Site
Bucharest, 030303, Romania
-
Investigative Site
Kyiv, 01135, Ukraine
-
Investigative Site
London, E1 1BB, United Kingdom
-
Investigative Site
London, SE5 9RS, United Kingdom
-
Investigative Site
Manchester, M8 5RB, United Kingdom
-
Investigative Site
Nottingham, NG7 2UH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hepatitis b drug showdown: which is safer for kidneys?
- New ultrasound technique aims to better measure liver health
- New Free-Breathing MRI could make liver scans easier for kids
- New MRI scan could replace liver biopsies
- New drug combo aims to tackle stubborn hepatitis d
- New drug duo takes on rare liver virus in head-to-head trial